Ender diagnostics enables rapid, high volume Covid-19 testing

Reliable and rapid testing has emerged as one of the most important factors in controlling and limiting the spread of infection in the COVID-19 pandemic. One of the most critical challenges around the world has been limited testing capacity in laboratories due to shortages of viral RNA extraction kits, testing reagents and qualified technicians.

The newly approved ender MASS by ender diagnostics enables detection in a simplified and accelerated process, considerably reducing the workload for medical professionals and laboratories. It is highly specific, easy-to-use and fast – providing results from a simple nasopharyngeal swab in only 30 minutes. The test is designed to enable on-site and pop-up labs to operate rapid testing in diverse settings, potentially including travel-related locations such as airports and cruise ships. The simplified workflows and analysis mean laboratories can process up to eight times as many tests compared to conventional PCR testing over the same period. US FDA clearance is anticipated in September 2020.

Tim Pfister, CEO of ender diagnostics, comments: «Constant rapid and flexible testing is the key to controlling the Covid-19 pandemic and enabling countries and economies around the world to open up and recover. Combined with a mobile lab infrastructure, the fast and easy-to-use ender MASS test would enable detection of coronavirus infection directly on-site in a wide range of locations, such as schools, hospitals, care homes, factories and in challenging locations such as airports and cruise ships prior to boarding. With a fully portable version of our testing system also advancing rapidly, ender diagnostics is well placed to make a significant contribution to helping avoid partial or large-scale lockdowns around the world.»